Biopharma is investing heavily in digital infrastructure. AI-enabled quality analytics, digital twins and algorithmic scheduling are no longer pilot projects; they are becoming the operating fabric of modern manufacturing and development environments.
And yet, across the sector, many organisations are not seeing the returns they expected. The reason is not the technology itself. It is the gap between digital maturity and workforce capability.
The four states of digital performance
BioTalent's Talent Science™ framework maps organisations across two axes: digital maturity and Talent Efficiency (TE) — a composite measure of capability density, onboarding velocity and workforce stability.
Organisations with high digital maturity and high TE demonstrate scalable performance, lower deviation rates and stronger margin stability. But those with high digital maturity and low TE tell a very different story: underutilised systems, override behaviours and elevated operational noise. The technology is there. The capability to leverage it is not.
BioTalent's analysis, supported by L.E.K. Consulting, shows that aligned organisations achieve an implied EV/EBITDA of 14.5x, compared to just 7.4x for misaligned firms — driven not by pipeline quality or capital availability, but by the alignment between digital systems and the people operating them.
Why the misalignment happens
Digitally mediated workflows now account for more than 60% of manufacturing process hours, up from under 25% in 2018. That shift demands hybrid technical roles, data-literate operators and systems integration capability at scale. In many organisations, the workforce has simply not kept pace with the infrastructure it is expected to run.
Talent Efficiency as the missing metric
The organisations navigating this most effectively treat Talent Efficiency as an operational metric — not an HR one. Workforce volatility is a leading indicator of performance deterioration: rising churn precedes margin erosion, capability loss increases deviation frequency and leadership instability delays milestone achievement. These are predictive signals — but only for organisations actively measuring them.
Digital transformation is, at its core, a capability transformation. AI ROI depends on capability density and stability as much as it depends on system architecture.
Download the full report
Pharma and Biotech 2030: Building the Execution Engine for the Next Decade of Biopharma brings together BioTalent's Talent Science™ insights with market and modality analysis, supported by L.E.K. Consulting, including a framework for building execution-ready organisations through 2030.